December 21, 2017 10:06 AM ESTUpdated December 22, 01:31 PM
News Briefing

Tra­con inks deal with Am­brx to de­vel­op can­cer drug in Chi­na; Roche wins con­sec­u­tive ap­provals in EU and US

Amber Tong

→ Two San Diego com­pa­nies have inked a li­cens­ing deal to de­vel­op a can­cer drug in Chi­na and Tai­wan. Am­brx gets ex­clu­sive rights to de­vel­op …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times